Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
RTS,S
| Vaccine description | |
|---|---|
| Target | P. falciparum; to a lesser extent Hepatitis B |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Mosquirix |
| Routes of administration | intramuscular injection (0.5 mL)[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
RTS,S/AS01 (trade name Mosquirix) is a recombinant protein-based malaria vaccine. It is one of two malaria vaccines approved (the other is R21/Matrix-M). As of April 2022[update], the vaccine has been given to 1 million children living in areas with moderate-to-high malaria transmission, with millions more doses to be provided as the vaccine's production expands.[3][4] 18 million doses have been allocated for 2023-2025.[5] It requires at least three doses in infants by age 2, with a fourth dose extending the protection for another 1–2 years.[3] The vaccine reduces hospital admissions from severe malaria by around 30% and reduces toddler deaths by 15%.[3][6]
- ^ Cite error: The named reference
emawas invoked but never defined (see the help page). - ^ "RTS,S Malaria Vaccine: 2019 Partnership Award Honoree". YouTube. Global Health Technologies Coalition. 15 November 2019. Retrieved 6 October 2021.
- ^ a b c Cite error: The named reference
npr-052022was invoked but never defined (see the help page). - ^ Cite error: The named reference
unicef-082022was invoked but never defined (see the help page). - ^ "18 million doses of first-ever malaria vaccine allocated to 12 African countries for 2023–2025: Gavi, WHO and UNICEF".
- ^ Wadman M (24 October 2023). "First malaria vaccine slashes early childhood mortality". Science.
Previous Page Next Page
